Highview Capital Management’s Boston Scientific BSX Stock Holding History

Highview Capital Management’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,836	Closed	-$1.61M	–	103
2025 Q4	$1.61M	Buy	16,836 +184	+1%	+$18K	0.57%	51
2025 Q3	$1.63M	Sell	16,652 -470	-3%	-$48.7K	0.6%	51
2025 Q2	$1.84M	Sell	17,122 -8,369	-33%	-$847K	0.71%	38
2025 Q1	$2.57M	Buy	25,491 +984	+4%	+$99.1K	1.08%	28
2024 Q4	$2.19M	Buy	24,507 +1,439	+6%	+$127K	0.84%	33
2024 Q3	$1.93M	Buy	23,068 +3,388	+17%	+$267K	0.79%	33
2024 Q2	$1.52M	Buy	19,680 +1,400	+8%	+$102K	0.63%	45
2024 Q1	$1.25M	Buy	18,280 +7,245	+66%	+$466K	0.56%	54
2023 Q4	$638K	Buy	+11,035	New	+$589K	0.34%	66

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Highview Capital Management's BSX Position: Q1 2026 in Review

Highview Capital Management sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 16,836 shares — an estimated $1.61M sold.

Highview Capital Management first reported a position in BSX in Q4 2023 and held it in 9 quarters. The position peaked at $2.57M in Q1 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Highview Capital Management reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Highview Capital Management sold 16,836 Boston Scientific shares in Q1 2026, an estimated $1.61M.
Highview Capital Management first reported a position in Boston Scientific in Q4 2023 and held it in 9 quarters.
Highview Capital Management's Boston Scientific position peaked at $2.57M in Q1 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Highview Capital Management's 13F filing for Q1 2026, filed 8 May 2026.